

ForPatients

by Roche

Crohn's Disease Ulcerative Colitis

A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease

Trial Status
Terminated

Trial Runs In
4 Countries

Trial Identifier
NCT03478956 2017-003649-10
CA40192

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate pharmacokinetics, pharmacodynamics and safety of etrolizumab in pediatric patients of 4 to <18 years of age with moderate to severe ulcerative colitis (UC) or with moderate to severe Crohn's disease (CD).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT03478956 2017-003649-10 CA40192
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>= 4 Years & <= 17 Years

Healthy Volunteers
No
